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Abstract RalGDS family members (RalGDS and RGL) inter- 
act with the GTP-bound form of Ras through its effector loop. 
The C-terminal region (amino acids 602-768) of RGL is respon- 
sible for binding to Ras. In this paper we characterized a Ras- 
interacting domain of RGL using deletion mutants of RGL(602- 
768). RGL(602-768), RGL(632-768), and RGL(602-734) bound 
to the GTP-bound form of Ras and inhibited the GAP activity 
of NF-1. RGL(646-768) showed a low binding activity to Ras and 
inhibited GAP activity of NF-1 weakly. None of RGL(659-768), 
RGL(685-768), RGL(602-709), and RGL(602-686) bound to 
Ras or inhibited GAP activity of NF-1. These results indicate that 
amino acids 632-734 of RGL constitute a nearly minimal domain 
that contains the binding element for Ras. RGL(632-734) inhib- 
ited v-Ras- but not progesterone-induced Xenopus oocyte matura- 
tion. Furthermore, RGL(632-734) inhibited v-Ras- but not v-Raf- 
dependent extracellular signal-regulated kinase activation in 
Xenopus oocytes. These results clearly demonstrate that the Ras- 
interacting domain of RGL is important for Ras-dependent signal 
transduction in vivo. 
Key words: RID; RGL; Ras; Extracellular signal-regulated 
kinase; Xenopus oocyte 
1. Introduction 
Ras is a member of small GTP-binding protein and is impor- 
tant for cell growth and differentiation [1-4]. Ras has the GDP- 
bound inactive and the GTP-bound active forms, and the GTP- 
bound form interacts with the effector proteins [1,3]. The inter- 
action of Ras with the effector proteins occurs through the 
effector loop of Ras (amino acids 32~J,0) [1,3]. The effector 
proteins of Ras have some activities that are regulated by its 
interaction with Ras, and the activities are responsible for some 
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of biological effects of Ras in the cells. Therefore, identification 
of the effector proteins which directly interact with the active 
form of Ras and exert biological effects has been a major goal 
of research of Ras to clarify the mode of action of Ras. 
Evidence has been accumulated that Ras has multiple effec- 
tor proteins uch as Raf-l, pl20-GAP, PI3-kinase, and MEKK 
[5-16]. Raf-1 is a serine/threonine kinase and activates ERK 
pathway [5-13]. The N-terminal domain of Raf-1 interacts with 
Ras through its effector loop. It has been found that about 80 
residues of Raf-1 constitute a binding domain for Ras [10,17 
20]. pl20-GAP interacts with the GTP-bound form of Ras and 
acts downstream of Ras in several signal transduction systems 
[14,21,22]. The catalytic domain of pl20-GAP is 343 residues 
of its C-terminus (amino acids 702-1044) and this domain is 
required for the interaction with the effector loop of the GTP- 
bound form of Ras [14]. However, it has been also suggested 
that pl20-GAP functions as a negative regulator of Ras [14]. 
p l l0  subunit of PI3-kinase associates with the GTP-bound 
form of Ras through its effector loop and nerve growth factor- 
dependent PI3-kinase activation is inhibited by a dominant 
negative mutant of Ras in PC12 cells, although the Ras-binding 
domain of PI3-kinase has not yet been determined [15]. How- 
ever, we have recently demonstrated that a constitutively active 
mutant of PI3-kinase stimulates the GDP/GTP exchange of 
Ras [23]. These results suggest hat PI3-kinase functions as a 
positive regulator of Ras. Whether GAP and PI3-kinase are the 
effector proteins of Ras might be dependent on cell types. 
MEKK binds to and is activated by the GTP-bound form of 
Ras [16,24]. The C-terminal kinase domain of MEKK interacts 
with Ras and the peptide corresponding to the effector loop of 
Ras blocks this interaction [16]. 
Three groups including us have found that RalGDS family 
members, RalGDS and RGL (RalGDS like), are new putative 
effector proteins of Ras [25-27]. RGL shares 70% amino acid 
homology with RalGDS [25,28]. RalGDS stimulates GDP/ 
GTP exchange of Ral [28]. Ral has been originally isolated by 
probing with an oligonucleotide corresponding to one of the 
GTP-binding domains of Ras [29]. Although the function of 
Ral has not yet been understood, RalGDS and RGL have been 
implicated in the regulation of the GTP state of Ral [25,28]. 
Therefore, it is possible that RalGDS and RGL mediate the 
signal from Ras to Ral. We have demonstrated that a 166- 
amino acid fragment (amino acids 603 768) of RGL binds to 
the GTP-bound form of Ras and designated this fragment as 
RID, Ras-interacting domain [25,30]. Although no homology 
in the primary structures of RGL(RalGDS), Raf-1, p 120-GAP, 
p110 of PI3-kinase, and MEKK has been found, it is speculated 
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that these molecules may share some structural similarities to 
bind to Ras. To determine how closely the Ras-interacting 
domains of RGL,  Raf-1, p l20-GAP,  p l l0  of PI3-kinase, and 
MEKK are situated in three dimension, and to identify the 
Ras-interacting residues of RGL  by X-ray crystal lography and 
NMR analysis, it is necessary to know the smallest R ID  of 
RGL.  In this paper, we show that a 103-amino acid fragment 
(amino acids 632-734) of RGL  is a nearly minimal domain that 
is containing the binding element for Ras. Furthermore,  we 
demonstrate that R ID  of RGL  inhibits the Ras-dependent sig- 
nal transduction in Xenopus oocytes. 
2. Materials and methods 
2.1. Materials and chemicals 
The NF-1 cDNA was provided by Dr. G. Xu (University of Utah, 
UT) [31]. pSP64T and pSP64T/v-Raf were provided by Dr. A. MacNi- 
col (University of Chicago, I L). pCGN, pGEX 1 R, pGEX2TR, pGI K S, 
and pGEX2T were provided by Drs. Q. Hu, D. Pot, and D. Milda 
(University of California, San Francisco, CA). [~-32p]GTP and [y- 
32p]GTP were purchased from DuPont NEN Research Product 
(Wilmington, DE). The anti-ERK antibody was from Santa Cruz Bio- 
technology (Santa Crutz, CA). v-Ras cDNA was synthesized by PCR 
as described [13]. c-Ras was purified to near homogeneity from the 
cytosol fraction of Sf9 cells expressing c-Ras [25,32]. To express the 
GST-fused to proteins in E. coli, transformed E. coli were initially 
grown at 37°C to an absorbance of 0.8 (600 nm) and subsequently 
transferred to 25°C. Then, isopropylthio-fl-D-galactoside was added at 
a final concentration f 0.1 mM and further incubation was carried out 
for 10 h at 25°C. The GST-fused to proteins were purified as described 
[25,33]. 
2.2. Plasmid constructions 
Deletion mutants of RGL(602 768) were constructed as follows. The 
oligonucleotide corresponding to the Myc epitope was synthesized by 
PCR. This oligonucleotide was designed to have the EcoRI site at the 
5' end and the BamHI site at the 3' end. pBSKS containing RID [25] 
was digested with XhoI and EcoRI. RID and the Myc epitope were 
ligated with pGEM7z which was digested with XhoI and BamHl to 
generate pGEM7z/RGL(602 768). To construct pGEX1R/RGL(602- 
768), pGEM7z/RGL(602-768) was digested with Xhol and BamHl and 
was inserted into the XhoI- and BamHI-cut pGEX1R. To construct 
pGEX2TR/RGL(632 768), about 0.5-kb fragment fused to the Myc 
epitope containing the KpnI and BamHI sites was synthesized by PCR. 
This fragment was digested with Kpnl and BamHI and inserted into the 
KpnI- and BamHI-cut pGEX2TR. To construct pGIKS/RGL(602 
734), about 0.5-kb fragment containing the KpnI and Sacl sites 
was synthesized by PCR. This fragment was digested with Kpnl and 
Sacl and inserted into the KpnI- and SacI-cut pGIKS. To con- 
struct pGEX2TR/RGL(64(~768), pGEX2TR/RGL(659-768), and 
pGEX2TR/RGL(685-768), the fragments fused to the Myc tag con- 
taining the Kpnl and BamHI sites were synthesized by PCR. These 
fragments were digested with KpnI and BamHI and inserted into the 
KpnI- and BamHI-cut pGEX2TR. To construct pGIKS/RGL(602 
709) and pGIKS/RGL(602 686), the fragments containing the Kpnl 
and SacI sites were synthesized by PCR. These fragments were digested 
with KpnI and SacI and inserted into the KpnI- and SacI-cut pGIKS. 
To construct pGEX2T/RGL(632 734), the fragment containing the 
BamHI and EcoRI sites was synthesized by PCR. This fragment was 
digested with BamHI and EcoRI and inserted into the BamHI- and 
EeoRI-cut pGEX2T. To construct pSP64T/RGL(632 734), pGEM7z/ 
RGL(632-734) was digested with BamH1 and EcoRI and both sites 
were blunted with Klenow fragment. This fragment was inserted into 
pSP64T which was digested with NcoI and SmaI (NcoI site was blunted 
with Klenow fragment), pSP64T/v-Ras and pSP64T/v-Raf were con- 
structed as described [23,34]. 
2.3. Binding assay of RID and Ras in vitro 
To make the GTP-bound form of Ras, Ras (2.5 pmol) was incubated 
for 5 min at 30°C in 5/~1 of preincubation mixture (50 mM sodium 
phosphate [pH 6.8], 5 mM EDTA, 2.5 mM MgCI2, 0.5 mg/ml BSA, 
0.5 mM DTT, and 0,5/zM [c~-32p]GTP [20,000-30,000 cpm/pmol]). To 
this preincubation mixture, 45/zl of reaction mixture (22 mM Hepes/ 
NaOH [pH 7.5], 2.2 mM Tris/HC1 [pH 7.5], 5.5 mM MgC12, 1.1 mg/ml 
BSA, 0.11 mM DTT, and 5.5/~M GTP) containing the indicated con- 
centrations of RGL fragments was added, and a second incubation was 
performed for 30 min at 4°C. RGL fragments were precipitated with 
glutathione Sepharose 4B, the precipitates were washed, and the re- 
maining radioactivities were counted. 
2.4. GAP assay of NF-1 
Ras (2.5 pmol) was preincubated for 5 min at 30°C in 5/tl of the same 
preincubation mixture described above except that [y-32p]GTP was 
used instead of [~-32p]GTP. To this preincubation mixture, 45 ¢tl of the 
same reaction mixture described above containing RGL fragments (50 
pmol) was added, and a second incubation was performed for 30 min 
at 4°C. Then, GST-NF-1 (0.5 pmol) was added and a third incubation 
was carried out for 15 min at 24°C. Assays were quantified by rapid 
fillration on nitrocellulose filters. GAP activity was calculated from the 
decrease of the radioactivity of [y-32p]GTP compared with a reaction 
performed in the absence of GST-NF-1, and GAP inhibition activity 
was expressed as percentage decrease of GAP activity of GST-NF-1. 
2.5. Maturation and ERK assays in Xenopus oocytes 
RNAs containing a 5'-GpppG cap were made by linearized plasmids 
of pSP64Tlv-Ras, pSP64T/v-Raf, or pSP64T/RGL(632-734) with the 
SP6 RNA polymerase as described [34-36] and resuspended in RNAase 
free water. Large oocytes (Dumount stage VI) were removed from adult 
female frogs. Oocytes were manually dissected and treated with collage- 
nase. Oocytes were maintained in 1 x-modified Barth's saline (10 mM 
Hepes/NaOH [pH 7.4], 88 mM NaC1, 1 mM KC1, 2.4 mM NaHCO3, 
0.82 mM MgSO4, 0.33 mM Ca(NO3)z, and 0.41 mM CaCI2), 1 mg/ml 
BSA, and 1 mg/ml Ficoll. Each oocyte was injected with 5 ng of RNA. 
Oocytes were incubated for 16 h at 18°C, and then some were treated 
with 2/~g/ml of progesterone. Oocytes were scored for the appearance 
of a white spot on the animal pole as an index of GVBD. Immunopre- 
cipitation of ERK from oocyte lysates was carried out as described [36]. 
ERK activity was determined by incubating the ERK immunoprecipi- 
tates with myelin basic protein (2/zg) in 30/11 of reaction mixture (50 
mM Hepes/NaOH [pH 7.5], 1 mM DTT, 10 mM MgCI2, and 50 ¢tM 
[y-32p]ATP [2000~4000 cpm/pmol]) for 30 rain at 24°C [36]. After the 
incubation, the samples were subjected to SDS-polyacrylamide g lelec- 
trophoresis, and the phosphoproteins were visualized by autoradiogra- 
phy. 
3. Results 
3.1. Ras-interacting domain of  RGL 
In order to investigate the domain of RGL  which might 
critically affect the interaction of RGL  with Ras, we con- 
structed eight overlapping fragments of RGL;  RGL(602-768), 
RGL(632-768), RGL(602-734),  RGL(646-768), RGL(659-  
768), RGL(685 768), RGL(602-709),  and RGL(602 686) (Fig. 
1). They were expressed as GST-fused to proteins in and puri- 
fied from E. eoli. RGL(602-768),  RGL(632 768), RGL(646-  
768), RGL(659 768), and RGL(685-768) were tagged with the 
Myc epitope at the C-terminal end. RGL(602 734), RGL(602-  
709), and RGL(602 686) were tagged with the HA epitope 
between GST and RGL fragments. To quantitate the Ras- 
binding activity of these RGL fragments, the [~-32p]GTP- 
bound form of Ras was incubated with RGL  fragments. 
RGL(602-768),  RGL(632 768), and RGL(602-734) showed a 
Kd value of 100 nM for the GTP-bound form of Ras (Fig. 2). 
Under  these conditions, about 0.5 pmol of Ras bound to 20 
pmol of RID. RGL(646-768) displayed weak interaction (Fig. 
2). None of RGL(659 768), RGL(685-768), RGL(602-709), 
and RGL(602-686) bound to Ras (Fig. 2). These results suggest 
that amino acids 632 734 of RGL  constitute a minimal domain 
to interact with Ras (Fig. 1). Indeed, RGL(632 734) bound to 
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RG L( 6 3 2- 7 3 4 ) ~///////////////////.//////////////////////////./~ 
Minimal Interacting 
Domain 
Fig. 1. Schematic structures of RGL fragments. The names of each 
RGL fragment, its first and last residues, are indicated. The hatched 
box indicates a possible minimal interacting domain with Ras. Light 
halftone symbol, the HA epitope; dark halftone symbol, the Myc epi- 
tope. 
the GTP-bound form of Ras with the affinity similar to 
RGL(602-768) (Fig. 2). 
3.2. GAP inhibition activity of RID of RGL 
It is known that GAP stimulates the GTPase activity of Ras 
by interacting with the effector loop of the GTP-bound form 
of Ras [14]. Therefore, we examined whether RGL fragments 
inhibited the GAP activity of NF-I .  None of RGL fragments 
had the GAP activity or the GDP/GTP exchange activity (data 
not shown). As expected, RGL(602 768), RGL(632-768), 
RGL(602-734), and RGL(632-734) inhibited strongly the GAP 
activity of NF-1, while RGL(646-768) inhibited weakly (Fig. 
3). None of RGL(659-768), RGL(685 768), RGL(602 709), 
and RGL(602-686) affected the GAP activity of NF-1 (Fig. 3). 
These results are consistent with those obtained in Fig. 2 and 
indicate that RID of RGL interacts with the effector loop of 
Ras. 
3.3. Inhibition of  v-Ras-induced oocyte maturation and ERK 
activation by RID of  RGL 
Finally, we examined the biological effect of a minimal Ras- 
interacting domain of RGL. Xenopus oocytes provide a conven- 
ient system to analyse signal transduction. Ras initiates matura- 
tion which associates with GVBD [37-39]. It is known that 
Raf-MEK-ERK pathway is involved in the Ras-induced 
GVBD and that progesterone initiates GVBD through Raf- 
MEK-ERK pathway, but does not require Ras [36-39]. Proges- 
terone is found to activate Raf-1 without Ras activation [36]. 
When 5 ng of RNA encoding v-Ras was injected into oocytes, 
GVBD was observed in 70% of oocytes (Fig. 4A). Injection of 
RGL(632 734) mRNA markedly reduced v-Ras-induced 
oocyte maturation. GVBD was observed in only 20% of 
oocytes injected with both of v-Ras and RGL(632-734) 
mRNAs (Fig. 4A). On the other hand, injection of RGL(632- 
734) mRNA did not affect progesterone-induced maturation 
(Fig. 4A). These results indicate that RGL(632-734) specifically 
binds to the active form of Ras and that it blocks Ras-depend- 
ent signal transduction. Since ERK activation is required for 
oocyte maturation [38,39], we investigated whether RGL(632- 
734) affected ERK activity. Coinjection of RGL(632-734) 
mRNA with v-Ras mRNA suppressed v-Ras-dependent ERK 
activity (Fig. 4B). However, coinjection of RGL(632-734) 
mRNA with v-Raf mRNA did not affect v-Raf-dependent 
ERK activity (Fig. 4B). 
4. Discussion 
We have determined a domain in the C-terminal region of 
RGL to bind to Ras with a high affinity. Our results indicate 
that the 103-amino acid residues of RGL(632-734) constitute 
a nearly minimal domain that contains the binding elements for 
Ras (Fig. 1), since RGL fragments which do not include whole 
of this domain neither interact with Ras nor inhibit the GAP 
activity of NF-1. RGL(632-734) shares about 80% amino acid 
homology with RalGDSa(721-821) and RalGDSb(764-864). 
In the overall sequences of RGL and RalGDS, these regions 
share the highest homology with each other. It has been found 
that RalGDSa(726-852) and RalGDSb(767-864) interact with 
Ras [26,27]. Therefore, these regions could be critical for the 
binding of RalGDS family to Ras. 
Among the effector proteins of Ras, Raf-1 has been exten- 
sively studied [5-13]. Biochemical analysis has shown that the 
80-amino acid residues of Raf(51-130) constitute a minimal 
binding domain to Ras [10,17-20]. The X-ray crystal structure 
of the complex between the Ras-binding domain of Raf-1 and 
Rap, a Ras-related small GTP-binding protein, has been solved 
[40]. It shows that an antiparallel f -sheet is formed by the 
fl-sheet (amino acids 66-71) from Ras-binding domain of Raf-1 
and the/J-sheet (amino acids 36-45) from Ras. Since RID of 
RGL does not show any homology with Ras-binding domain 
of Raf-1, it is not known which amino acid residues of RID are 
critical for its interaction with Ras. By analogy with the interac- 
tion of Ras and Raf-1, the fl-sheet structure in RID might be 
important. Other putative effector proteins of Ras such as 
GAP, PI3-kinase, and MEKK do not share any homology with 
Raf-1 in their primary structures, either. These results also 
suggest that not primary but secondary or tertiary structure of 
i i i , , 
,_,10 
RGL fragments (ixM) 
Fig. 2. Binding activity of RGL fragments to Ras. The [~-32p]GTP- 
bound form of Ras was incubated with the indicated concentrations of
the RGL fragments for 30 min at 4°C. The mixtures were precipitated 
with glutathione S pharose 4B and the radioactivities ofthe precipitates 
were counted. (e---e), RGL(602-768); (m--II), RGL(632-768); (~©),  
RGL(602 734); ([]--D), RGL(64(~768); (~4) ,  RGL(659 768); 
(m- m), RGL(685 768); (©-~), RGL(602 709); ([] G), RGL(602 
686); (~--A), RGL(632 734). The results hown are representative of 
three independent experiments. 
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Ras-binding domain of Ras-effector proteins is important to 
interact with Ras. It is necessary to clarify the X-ray crystal 
structure of these effector proteins of Ras to understand the 
interaction of Ras with its effector proteins. 
Our results have shown that RGL(632 734) inhibits v-Ras- 
but not progesterone-induced oocyte maturation. It is known 
that the anti-Ras antibody, Y13 259 (the neutralizing anti- 
body), blocks Ras- but not progesterone-induced oocyte matu- 
ration and that progesterone does not require Ras to induce 
oocyte maturation [37]. Therefore, our results indicate that a 
direct interaction between Ras and R ID is sufficient o inhibit 
the Ras action. Since RalGDS has been found to inhibit the 
interaction of Ras with Raf-1 in vitro [25-27], it is possible that 
R ID  of RGL  interferes their association in vivo, resulting in 
inhibiting Ras-dependent Raf-1 activation. Consistent with 
this, our results have demonstrated that R ID inhibits v-Ras- 
but not v-Raf-dependent ERK activation. Taken together, 
these results indicate that R ID blocks at least Ras-dependent 
signal transduction through Raf-1, suggesting that R ID can be 
utilized as a tool to analyse the function of Ras. The effect of 
R ID  on Ras-dependent signal pathway through the effector 
proteins other than Raf-1 remains to be clarified. 
It is conceivable that Ra lGDS and RGL  mediate the signal 
from Ras to Ral [25 27]. Although the function of Ral is not 
clear, RalBP1 has been found to be a putative effector protein 
of Ral [41,42]. RalBP1 shows the GAP activity for CDC42 and 
Rac 1, members of small G proteins which regulate the cytoskel- 
eton and SAPK activation [4345]. Taken together with the 
observations that a dominant negative mutant of Rac reverses 
the v-Ras-dependent transformation [46,47], it is intriguing to 
speculate that there is a new signal pathway consisting of Ras- 
RalGDS(RGL)-Ral-RalBP1-CDC42/Rac.  Furthermore, re- 
cently it has been reported that Ral interacts with phospholip- 
ase D and that Ras-dependent phospholipase D activity is in- 
hibited by a dominant negative mutant of Ral [48]. Therefore, 
the new signal pathway from Ras to Ral could be important. 
It is necessary to develop the specific inhibitor for this new 
signal pathway to clarify the role of this pathway. One possible 
approach is to produce the anti-RID antibody which inhibits 
~z0 
0 
602-768 602.734 646-768 685.768 602-686 
632-768 632-734 659-768 602-709 
RGL fragments 
Fig. 3. Inhibition of GAP activity of NF-1 by RGL fragments. After 
the [T-32p]GTP-bound form of Ras was incubated with 1 /IM RGL 
fragments for 30 rain at 4°C, the mixture was incubated with 10 nM 
GST-NF-1 for 15 rain at 24°C. The mixtures were then collected on 
filters, and the radioactivities were counted. GAP inhibition activily 
was expressed as percentage decrease of GAP activity of GST-NF-1. 
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Fig. 4. Inhibition of v-Ras-dependent signal transduction i Xenopus 
oocytes by RGL(632 734). (A) Oocyte maturation. At least 50 oocytes 
were injected with water (lanes 1 and 5) or RNAs of RGL(632 734) 
(lanes 2 and 6), v-Ras (lane 3), or both v-Ras and RGL(632 734) (lane 
4). Some oocytes (lanes 5 and 6) were treated with progesterone. The 
numbers of oocytes on which a white spot appeared were scored and 
the percentage of GVBD was expressed as an index of maturation. 
(B) ERK activity. At least 50 oocytes were injected with water (lane 1) 
or RNAs of RGL(632-734) (lane 2), v-Ras (lane 3), both v-Ras and 
RGL(632 734) (lane 4), v-Raf (lane 5), or both v-Raf and RGL(632 
734) (lane 6). ERK activity was measured using myelin basic protein 
as a substrate. The results shown are representative of three independ- 
ent experiments. 
the interaction of Ras with RID. Screening to find this antibody 
is now under way. 
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